Pharma takes major decisions to focus on production of coronavirus vaccine

0
3

Pfizer said on Friday it is in talks to shift more of its medicine production to outside contractors as it prepares for large-scale production of an experimental vaccine to prevent COVID-19, should it prove safe and effective. The U.S. drugmaker is tapping its network of around 200 outside contractors, which includes Catalent, Lonza Group, and Thermo Fisher Scientific, to play a bigger role in producing some of its existing medicines, Mike McDermott, president of global supply at Pfizer, told Reuters in an interview.

NO COMMENTS